Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

The First Affiliated Hospital of Dalian Medical University1,505 enrolled

Overview

The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.

Study Type

OBSERVATIONAL

Enrollment

1,505

Conditions

Platelet Aggregation Inhibitors Dual Anti-Platelet Therapy Aged Percutaneous Coronary Intervention

Interventions

TicagrelorDRUG

Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.

Eligibility

Sex: ALLMin age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age≥75 years old; * Treated with PCI (limited to stent implantation) ; * Survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at discharge; Exclusion Criteria: * Coronary artery bypass graft (CABG) or only drug conservative treatment during hospitalization; * Concurrent use of oral anticoagulants; * Inability to tolerate long-term antiplatelet therapy, such as active bleeding and a bleeding tendency; * Acute infectious diseases; * Cognitive impairment; * Declined re-examination.

Locations (1)

The First Affiliated Hospital of Dalian Medical University

Dalian, China

Outcomes

Primary Outcomes

Types 2, 3, and 5 bleeding, as defined by the Bleeding Academic Research Consortium

The primary safety endpoint

Time frame: 12 months

Combined major adverse cardiovascular and cerebrovascular events (MACCEs), including all-cause mortality, myocardial infarction, ischemic stroke, and any revascularization.

The primary efficacy endpoint

Time frame: 12 months

Secondary Outcomes

All-cause mortality

Time frame: 12 months

Myocardial infarction

Time frame: 12 months

Revascularization

Time frame: 12 months

Ischemic stroke

Time frame: 12 months

Incidence of BARC3 and 5 bleeding

Time frame: 12 months

Incidence of major and minor bleeding defined by the PLATO study

Time frame: 12 months

Incidence of major and minor bleeding defined by the TIMI study

Time frame: 12 months

Occurrence of any bleeding

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.